CCT-717

CCT-717 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Canary Cure for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The drug is part of Canary's "Thermogenic Adipose Reprogramming" platform, which utilizes AI-driven siRNA target selection to identify and modulate pathways involved in thermogenesis and energy balance. By silencing specific genetic targets that regulate energy expenditure in adipose tissue, CCT-717 aims to promote weight loss and improve metabolic health. It is designed for subcutaneous administration, potentially offering a long-acting dosing schedule similar to other assets in the company's pipeline.